Cronos Group Inc.

Cronos reported second-quarter consolidated net revenue of $53 million, up 58% year over year. Gross profit was $28.5 million, up 96% year over year, and adjusted EBITDA was a record $13.1 million, up $11.4 million year over year. Total operating expenses were $21 million, up $1.2 million year over year, including $500,000 of transaction costs tied to the pending CanAdelaar acquisition. The company ended the quarter with $827 million in cash, cash equivalents, short-term investments, and non-current interest-bearing deposits, up $5 million from Q1, helped by $24 million of operating cash flow and partly offset by $60 million of share repurchases and $2 million of CapEx. Management did not provide explicit next-quarter or full-year financial guidance on this call.

Mike Gorenstein framed the quarter as a broad-based operational win, saying Cronos delivered a “stellar” quarter with records across net revenue, gross profit, and adjusted EBITDA. He emphasized the company’s borderless product strategy, pointing to momentum in Israel, Canada, and other international markets, and highlighted the planned CanAdelaar deal as a way to extend Spinach, SOURZ, and PUFFERZ into an adult-use market. He also portrayed the company as strategically flexible, with a strong balance sheet, positive operating cash flow, and a willingness to keep buying back stock while staying open to opportunistic investments.

Anna Shlimak said the revenue increase was driven mainly by higher cannabis flower sales in Israel, Canada, and Germany, plus higher Canadian extract sales. She attributed the gross profit improvement to higher average selling prices from mix shifting toward Israel and other non-excise-tax markets, higher sales volumes, and better overhead absorption from stronger production; she also noted seasonally better growing conditions and said gross margin can vary with seasonality, mix, production volumes, and price compression. She said operating expenses rose to $21 million, with $500,000 of the increase tied to CanAdelaar-related transaction costs, and detailed liquidity of $827 million plus $17 million of loan receivable, $15 million of current income tax receivable, and $5 million of other investments.

Analysts focused on Spinach’s ability to cross categories and borders, the strength of Germany despite price pressure, gross margin drivers, GrowCo integration, Israel supply chain flexibility amid the anti-dumping probe, and Cronos’ U.S. strategy. Management said Spinach’s success comes from treating each product like a new launch, and that CanAdelaar could help translate brands like SOURZ and PUFFERZ into Dutch adult-use; on Germany, Gorenstein said the business is winning with product/value rather than local boots on the ground and that added capacity has increased focus on Europe. He also said Israel sales include product sourced domestically, from third parties, and from GrowCo, and for the U.S. he described a future entry focused more on borderless products and IP than heavy cultivation infrastructure if the market stays state-based.